Although bromodomain and extraterminal domain (BET) proteins were not described in our review because they are not epigenetic modifiers but epigenetic readers involved in transcriptional regulation, it is important to highlight that BET inhibitors can sensitize BRCA-proficient tumours to PARPi by downregulating several HR-related factors, including BRCA1, thus inducing the BRCAness phenotype [95,96,97]. The gene discussed is BRCA1; the disease is neoplasm.